4//SEC Filing
ANDO DALE G 4
Accession 0001181431-13-019376
CIK 0001001233other
Filed
Mar 27, 8:00 PM ET
Accepted
Mar 28, 5:44 PM ET
Size
12.5 KB
Accession
0001181431-13-019376
Insider Transaction Report
Form 4
ANDO DALE G
VP, Therapeutic Dev. & CMO
Transactions
- Exercise/Conversion
Common Stock
2013-03-26$3.61/sh+9,200$33,212→ 103,798 total - Exercise/Conversion
Employee Stock Option (Right to Buy)
2013-03-26−5,800→ 0 totalExercise: $3.61Exp: 2014-08-01→ Common Stock (5,800 underlying) - Sale
Common Stock
2013-03-26$9.18/sh−15,000$137,724→ 88,798 total - Exercise/Conversion
Common Stock
2013-03-26$3.61/sh+5,800$20,938→ 94,598 total - Exercise/Conversion
Employee Stock Option (Right to Buy)
2013-03-26−9,200→ 80,000 totalExercise: $3.61Exp: 2014-08-01→ Common Stock (9,200 underlying)
Footnotes (4)
- [F1]The sales reported in this Form 4 were effected pursuant to the Rule 10b5-1 trading plan adopted by the Reporting Person on June 26, 2012, as amended on September 12, 2012.
- [F2]Includes 50,000 shares and 35,000 shares subject to restricted stock units granted on December 8, 2011 and December 6, 2012, respectively, which will be issued as such units vest in accordance with their terms.
- [F3]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.08 to $9.30, inclusive. The Reporting Person undertakes to provide to Sangamo BioSciences, Inc., any security holder of Sangamo BioSciences, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range.
- [F4]All shares underlying this option are vested and immediately exercisable.
Documents
Issuer
SANGAMO BIOSCIENCES INC
CIK 0001001233
Entity typeother
IncorporatedDE
Related Parties
1- filerCIK 0001202278
Filing Metadata
- Form type
- 4
- Filed
- Mar 27, 8:00 PM ET
- Accepted
- Mar 28, 5:44 PM ET
- Size
- 12.5 KB